Nicox (DB:NXOA) - Cotización, noticias y análisis

Resumen de acción NXOA

Nicox S.A. opera como empresa oftalmológica en Francia y a escala internacional.

NXOA fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	2/6
Past Performance	0/6
Financial Health	2/6
Dividends	0/6

Recompensas

Se prevé un crecimiento anual de los ingresos de 70.28%

Análisis de riesgos

Volatilidad del precio de la acción en los últimos 3 meses

Actualmente no es rentable y no se prevé que lo sea en los próximos 3 años

No tiene ingresos significativos (€4M)

No tiene una capitalización de mercado significativa (€19M)

Competidores de Nicox S.A.

Medigene

XTRA:MDG1

€37.9m

co.don

XTRA:CNW

€6.5m

Epigenomics

XTRA:ECX

€1.4m

Paion

XTRA:PA8

€2.6m

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for Nicox
Historical stock prices
Current Share Price	€0.33
52 Week High	€0.60
52 Week Low	€0.26
Beta	0.89
1 Month Change	-4.07%
3 Month Change	-13.16%
1 Year Change	-42.41%
3 Year Change	-92.14%
5 Year Change	-93.29%
Change since IPO	-99.20%

Noticias y actualizaciones recientes

Recent updates

Rentabilidad de los accionistas

	NXOA	DE Biotechs	Mercado DE
7D	-3.6%	2.2%	-1.0%
1Y	-42.4%	-22.2%	2.2%

Rentabilidad vs. Industria: NXOA obtuvo unos resultados inferiores a los del sector German Biotechs , que el año pasado arrojó un rendimiento del -24.4%.

Rentabilidad vs. Mercado: NXOA obtuvo unos resultados inferiores a los del mercado German, que fue del 1.3% el año pasado.

Volatilidad de los precios

Is NXOA's price volatile compared to industry and market?
NXOA volatility
NXOA Average Weekly Movement	8.0%
Biotechs Industry Average Movement	5.1%
Market Average Movement	4.9%
10% most volatile stocks in DE Market	10.3%
10% least volatile stocks in DE Market	2.5%

Precio estable de las acciones: El precio de las acciones de NXOA ha sido volátil en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de NXOA(8%) se ha mantenido estable durante el último año, pero sigue siendo superior al 75% de las acciones de German.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
1996	28	Gavin Spencer	www.nicox.com

Nicox S.A. opera como empresa oftalmológica en Francia y a escala internacional. La empresa desarrolla soluciones para mantener la visión y mejorar la salud ocular. Su principal producto candidato es NCX 470, un novedoso colirio de bimatoprost donador de óxido nítrico para reducir la presión intraocular en pacientes con glaucoma de ángulo abierto o hipertensión ocular, que se encuentra en fase 3 de ensayo clínico.

Resumen de fundamentos de Nicox S.A.

¿Cómo se comparan los beneficios e ingresos de Nicox con su capitalización de mercado?
Estadísticas fundamentales de NXOA
Capitalización bursátil	€19.00m
Beneficios(TTM)	-€17.36m
Ingresos (TTM)	€3.57m

5.3x

Ratio precio-ventas (PS)

-1.1x

Ratio precio-beneficio (PE)

¿Está NXOA sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de NXOA
Ingresos	€3.57m
Coste de los ingresos	€16.90m
Beneficio bruto	-€13.33m
Otros gastos	€4.03m
Beneficios	-€17.36m

Últimos beneficios comunicados

Jun 30, 2023

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	-0.35
Margen bruto	-372.97%
Margen de beneficio neto	-485.70%
Ratio deuda/patrimonio	44.8%

¿Cómo se ha desempeñado NXOA a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción NXOA

Recompensas

Análisis de riesgos

Competidores de Nicox S.A.

XTRA:MDG1

€37.9m

XTRA:CNW

€6.5m

XTRA:ECX

€1.4m

XTRA:PA8

€2.6m

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Nicox SA Receives Confirmation of 5-Year Patent Term Extension of U.S. Patent for Latanoprostene Bunod, Commercialized as VYZULTA

Nicox's Announces Publication of New Nonclinical Data Demonstrating More Effective Intraocular Pressure Lowering of NCX 470 Compared to Lumigan

New major risk - Revenue and earnings growth

First half 2023 earnings released: €0.13 loss per share (vs €0.39 loss in 1H 2022)

New major risk - Revenue and earnings growth

Nicox S.A. to Report Q2, 2023 Results on Jul 19, 2023

Recent updates

Nicox SA Receives Confirmation of 5-Year Patent Term Extension of U.S. Patent for Latanoprostene Bunod, Commercialized as VYZULTA

Nicox's Announces Publication of New Nonclinical Data Demonstrating More Effective Intraocular Pressure Lowering of NCX 470 Compared to Lumigan

New major risk - Revenue and earnings growth

First half 2023 earnings released: €0.13 loss per share (vs €0.39 loss in 1H 2022)

New major risk - Revenue and earnings growth

Nicox S.A. to Report Q2, 2023 Results on Jul 19, 2023

Full year 2022 earnings released

Nicox S.A., Annual General Meeting, Feb 28, 2023

Nicox S.A., Annual General Meeting, Feb 14, 2023

Nicox S.A. Outlines Future Development and Partnering Plans for Ncx 470 in Glaucoma

Nicox S.A. Reports Achieving Primary Objective in Mont Blanc, the First Phase 3 Glaucoma Trial for NCX 470

Nicox S.A. Announces Last Patients Complete Final Visit in Ncx 470 Phase 3 Mont Blanc Glaucoma Trial

First half 2022 earnings released: EPS: €0 (vs €0.32 loss in 1H 2021)

Nicox Appoints Jean-Francois Labbé as Chairman of the Board of Directors

Nicox Announces Publication of NCX 470 Results Demonstrating Improvements to Ocular Hemodynamics and Retinal Cell Physiology

Nicox S.A., Annual General Meeting, Jun 28, 2022

Nicox S.A. Accelerates Topline Results from NCX 470 Mont Blanc Phase 3 Glaucoma Trial to November 2022

Nicox S.A. Announces Executive Changes

Nicox S.A., Annual General Meeting, Jun 14, 2022

Full year 2021 earnings released: €1.17 loss per share (vs €0.54 loss in FY 2020)

Nicox’s NCX 470 Dolomites Phase 2 Results Published in Journal of Glaucoma

Nicox’s Partner Ocumension Obtains Positive Phase 3 Clinical Trial Results for ZERVIATE® in China

Nicox Announces VYZULTA Now Commercialized in 7 Territories and Approved in Further 9 Countries

Nicox S.A. Announces Chinese National Intellectual Property Administration Grant A Formulation Patent for NCX 470

Nicox’s Positive FDA Meeting Shows Clear Path for NCX 4251 in Dry Eye

Nicox Announces First Patient in China screened in the ongoing NCX 470 Denali Phase 3 Trial in Glaucoma

Nicox S.A. Announces Positive Post Hoc Results from Its Mississippi Phase 2B Clinical Trial Suggesting That Once-Daily Dosed NCX 4251

Nicox SA Reports New Data on NCX 470 in Nonclinical Model of Retinal Cell Damage Induced by Endothelin-1

First half 2021 earnings released

Nicox S.A. Announces Results from the NCX 4251 Phase 2B Mississippi Blepharitis Trial

High number of new and inexperienced directors

Nicox Announces Last Patient Completed NCX 4251 Mississippi Phase 2B Blepharitis Trial

Nicox SA Presented Results from the Dolomites Phase 2 Clinical Trial Showing That NCX 470

Nicox’s Licensee Bausch + Lomb Receives Approval for VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024% in the United Arab Emirates

Nicox SA to Present NCX 470 Dolomites Phase 2 Results in Glaucoma Patients at the World Glaucoma E-Congress 2021

Nicox's Completes Pre-Defined Enrollment of NCX 4251 Mississippi Phase 2b Blepharitis Trial

Nicox’s Licensee Bausch + Lomb Launches VYZULTA® (Latanoprostene Bunod Ophthalmic Solution), 0.024% in Taiwan and Receives Approval in Qatar

U.S. Patent Office Issues Notice of Allowance for Nicox’s Latanoprostene Bunod in Normal Tension Glaucoma

Nicox S.A., Annual General Meeting, Apr 14, 2021

Full year 2020 earnings released

Nicox S.A. to Report Fiscal Year 2020 Results on Mar 01, 2021

Nicox Announces the Publication in Leading Scientific Journal of Pre-Clinical Efficacy Results on a New Class of Non-PGA NO-donating IOP-Lowering Compounds

Nicox S.A. Licensee Bausch + Lomb Secures Approval of VYZULTA in Colombia

Nicox Initiates Phase 2b Trial of NCX 4251, a Potential First-in-Class Treatment for Blepharitis

Nicox’s Partner Fera Pharmaceuticals to Investigate Naproxcinod as Potential Covid-19 Adjuvant Treatment

Nicox S.A. has completed a Follow-on Equity Offering in the amount of €15.000651 million.

New 90-day high: €4.10

Nicox SA Initiates Second Phase 3 Trial of NCX 470 in Glaucoma

New 90-day low: €3.45

Nicox Announces Plans for NCX 4251 Phase 2 Trial in Blepharitis

Nicox Selects 0.1% NCX 470 Dose in Adaptive Stage of Mont Blanc Phase 3 Glaucoma Trial

New 90-day low: €3.61

Nicox SA Nicox Announces Senior Management Change

First half earnings released

Nicox S.A. to Report First Half, 2020 Results on Sep 10, 2020

New 90-day low - €3.67

GHO Capital Fund I LP managed by GHO Capital Partners LLP entered into an agreement to acquire remaining unknown minority stake in VISUfarma B.V from Nicox S.A. (ENXTPA:COX) for €5 million

Rentabilidad de los accionistas

Volatilidad de los precios